Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed follicular lymphoma that has relapsed or has failed primary therapy
Progressive disease requiring further treatment
Bidimensionally measurable disease
Acceptable hematologic status
Prestudy WHO performance status of 0, 1, or 2
Expected survival of \>/= 3 months
Patients with reproductive potential must follow accepted birth control methods during treatment and for 3 months after completion of treatment
Female patients must not be pregnant or lactating
Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, ABMT, or investigational drugs
You may not be if
Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks of first scheduled treatment (6 weeks if nitrosourea or mitomycin-C)
Prednisone or other immunosuppressive therapy within 3 weeks of first scheduled treatment
Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to first scheduled treatment
Previous exposure to IDEC-114 or any anti-CD80 antibody
ABMT within 6 months prior to first scheduled treatment
Abnormal liver function
Abnormal renal function
Presence of chronic lymphocytic leukemia (CLL)
Presence of CNS lymphoma
Presence of HIV infection or AIDS
Prior diagnosis of aggressive non-Hodgkin's lymphoma or mantle-cell lymphoma
Another primary malignancy (other than squamous cell and basal cell carcinoma of the skin, in situ carcinoma of the cervix, or treated prostate cancer with a stable PSA) for which the patient has not been disease-free for at least 3 years
Serious nonmalignant disease which would compromise protocol objectives in the opinion of the investigator and/or the sponsor
New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to first scheduled treatment
Major surgery, other than diagnostic surgery, within 4 weeks prior to first scheduled treatment
Pleural invasion and/or effusion with positive cytology for lymphoma
Peritoneal invasion and/or ascites with positive cytology for lymphoma
